US Stock Market Move | Due to the emergence of the second case of gene therapy-related death, Sarepta Therapeutics (SRPT.US) plunged more than 47%.

On Monday, Sarepta Therapeutics (SRPT.US) plunged over 47%, hitting its lowest price since June 2016, now trading at $18.89. In terms of news, the company disclosed a second case of acute liver failure related to its Duchenne muscular dystrophy treatment drug Elevidys, which resulted in the death of a patient. The company stated that they are taking measures to focus on safety, including temporarily suspending the shipment of the treatment drug to non-ambulatory patients, while evaluating enhanced immunosuppression protocols.